FDA Fast-Tracks Blood Test That Catches Missed Strokes

When stroke patients arrive at the hospital, doctors race against time to figure out what's happening inside the brain. Every minute of delay means more brain cells die, yet nearly one in six strokes gets missed on the first diagnosis.

That sobering reality drove two Cornell researchers to develop something that could change everything. Dr. Alexander Travis and Dr. Roy Cohen created a rapid blood test that can detect acute ischemic stroke, the most common type, in minutes instead of hours.

The technology works by identifying a specific biomarker in the blood that signals when this type of stroke is occurring. What makes it revolutionary is its speed and simplicity compared to current diagnostic methods that often rely on imaging and clinical assessment alone.

The researchers didn't stop at the laboratory bench. They partnered with Cornell Trustee Emeritus David Fischell to launch TETmedical, a company dedicated to bringing the test from research into real-world medical care.

Their effort just hit a major milestone. The FDA granted Breakthrough Device Designation to NSE-FAST, recognizing it as the first rapid blood test designed to help diagnose acute ischemic stroke.

The Ripple Effect

This designation does more than validate the science. It opens an accelerated pathway for collaboration with the FDA, potentially shaving years off the typical approval process for new medical devices.

For patients, the impact could be profound. Faster, more accurate stroke diagnosis means doctors can start the right treatment sooner, which directly translates to better recovery outcomes and preserved brain function.

The technology addresses a critical gap in emergency medicine where time pressure and diagnostic uncertainty collide. Missed or delayed stroke diagnoses significantly increase the risk of cognitive impairment, permanent disability, and death.

What started as animal health research at the Baker Institute evolved into a potentially life-saving tool for humans. It's a reminder that breakthroughs often emerge from unexpected places when curious minds pursue solutions to urgent problems.

The test still needs to complete clinical trials and receive full FDA approval before reaching hospitals nationwide, but the breakthrough designation signals confidence in its potential to transform stroke care.

Thousands of stroke patients and their families may soon benefit from a discovery that began in a veterinary research lab and grew into hope for faster, more accurate diagnoses when every second counts.